Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
CN |
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
12.2B CNY | 11 | ||
US |
Mckesson Corp
NYSE:MCK
|
71.7B USD | 20 | ||
US |
Cencora Inc
NYSE:COR
|
44.3B USD | 22 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 13.7 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.8B USD | 12.3 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD | 24.7 | ||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
70.4B HKD | 5.1 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -285 | |
IT |
Amplifon SpA
MIL:AMP
|
7.7B EUR | 31.6 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
58.8B CNY | 28.9 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
53B CNY | 32.4 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.